The device was not returned for analysis.A review of the lot history record identified no manufacturing nonconformities issued to the reported lot that would have contributed to this event.A conclusive cause for the reported patient effect(s), and the relationship to the product, if any, cannot be determined; however, the subsequent treatment appears to be related to the operational context of the procedure.The reported patient effects of angina and stenosis are listed in the xience alpine everolimus eluting coronary stent system (eifu), electronic instructions for use as a known patient effects of coronary stenting procedures.There is no indication of a product quality issue with respect to manufacture, design or labeling.
|
It was reported that on (b)(6) 2022, the patient had percutaneous transluminal coronary angioplasty (ptca) in the left main (lm) artery to the left anterior descending (lad) and the left circumflex artery.A 3.5x28mm xience alpine stent was successfully implanted.On (b)(6) 2024 the patient presented with chest pain and angiography was performed.In-stent restenosis was noted in the lm to lad artery in the mid segment of the stent.On (b)(6) 2024, three cutting balloons and three drug-eluting balloons were used to treat the restenosis.There was no adverse patient sequela.No additional information was provided.
|